Harriet  Kluger, MD

Harriet Kluger, MD

Yale Cancer Center/Smilow Cancer Hospital

Harvey and Kate Cushing Professor of Medicine (Oncology) and of Dermatology; Director, Yale SPORE in Skin Cancer, Yale Cancer Center; Vice Chair for Translational Research, Internal Medicine; Chief, Division of Skin and Kidney Cancer; Associate Cancer Center Director, Education, Training and Faculty Development; Deputy Section Chief, Medical Oncology

Expertise: Medical OncologySkin CancerMelanoma







Dr. Kluger is a medical oncologist who sees patients with melanoma and renal cell carcinoma. Her research interests focus on developing new drug regimens and biomarkers predictive of response to therapies in melanoma and renal cell carcinoma. She participates in a number of clinical trials studying new agents for the treatment of these diseases, both targeting the immune system and the cancer cell. She runs an active research laboratory that studies tumor and immune cells from patients treated with novel therapies to determine mechanisms of resistance to therapy and mediators of toxicity from immune checkpoint inhibitors. The laboratory also conducts pre-clinical studies to improve treatment regimens for patients with melanoma, renal cell carcinoma or brain metastasis.
Please visit the lab website at:
https://sites.google.com/yale.edu/hklugerlab/home?authuser=3

Education & Training:
Fellow-Yale University School of Medicine (2002)
Resident-University of New Mexico (1995)
MD-Tel Aviv University (1993)

No Clipping

No Research/Citations

Immunotherapy for metastatic cancer on the rise, even near end of life

A new study led by Yale Cancer Center researchers at Yale School of Medicine found that while the initiation of immunotherapy near the end of life has increased over time, a closer look at the benefit and value of these therapies in patients with advanced-stage disease is needed.
04-Jan-2024 12:05:42 PM EST

Yale Scientists Identify Immune Cells Critical for Immunologic Memory for Melanoma

Immune-checkpoint inhibitors have become the standard of care for patients with advanced melanoma to improve survival, but only some patients respond to this immunotherapy and have long-term benefits. The lack of a long-lasting response, researchers say, is related to failure of antitumor immunologic memory. Treatment options for advanced melanoma are limited for patients who do not respond to this type of therapy.
27-Jul-2023 12:30:36 PM EDT

No Quotes

Available for logged-in users onlyLogin HereorRegister

No Video

close
0.07697